Mupirocin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using the drug-repurposing evidence pack you provided, here is the evaluation report. Note on judgement call: predicted_indications[0] (Pleural Empyema) carries the highest raw TxGNN score, but the evidence pack’s own mechanistic rationale argues against its plausibility (Mupirocin is topical-only). I have followed the template literally for the headline indication (as instructed) while being transparent about why the evidence does not support it, and I flag the pack’s best-supported alternative (Staphylococcal Scalded Skin Syndrome, rank 9) in the conclusion so the reader isn’t misled by the score alone.
Mupirocin: From Topical Staphylococcal Skin Infections to Pleural Empyema
One-Sentence Summary
Mupirocin is a topical antibacterial agent used against Gram-positive skin and soft-tissue infections (e.g. impetigo) and for nasal Staphylococcus aureus decolonisation. The TxGNN model assigns its highest repurposing score to Pleural Empyema (99.49%), but this prediction is supported by zero clinical trials and zero publications, and mechanistic review indicates that a topical-only formulation cannot plausibly reach a deep pleural space infection.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Topical antibacterial for Gram-positive skin/soft-tissue infections (e.g. impetigo, nasal S. aureus decolonisation) — no formal marketing-authorisation indication text is available in this dataset |
| Predicted New Indication | Pleural Empyema |
| TxGNN Prediction Score | 99.49% |
| Evidence Level | L5 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Formal mechanism-of-action data for Mupirocin is not available in this dataset (data gap). However, evidence embedded elsewhere in this pack indicates that Mupirocin’s established pharmacological target is bacterial isoleucyl-tRNA synthetase (IleRS), which blocks bacterial protein synthesis and underlies its activity against Gram-positive organisms, principally Staphylococcus aureus and Streptococcus pyogenes.
Pleural empyema is typically a deep, often polymicrobial (including anaerobic and Gram-negative) pleural-space infection requiring systemic antibiotic therapy with adequate pleural penetration, sometimes combined with drainage. Mupirocin, by contrast, is formulated exclusively for topical (skin/nasal) use and has no established systemic pharmacokinetic profile. There is no plausible route by which a topical ointment could reach the pleural cavity in therapeutic concentrations.
Our assessment is that the very high TxGNN score most likely reflects a generic knowledge-graph association with S. aureus infection (empyema can be staphylococcal in origin) rather than a specific, deliverable treatment pathway. In the absence of any supporting trial or literature evidence, and given the fundamental route-of-administration mismatch, this prediction should currently be treated as a model artefact rather than a credible repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No marketing authorisations are currently recorded for Mupirocin in this dataset (total_licenses: 0, market status: Not Marketed). No product-level dosage form or approved-indication text can therefore be extracted for this evaluation.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: retrieval of the MHRA-approved warnings/contraindications for Mupirocin is flagged in the underlying evidence pack as a blocking data gap — see Conclusion below.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- The Pleural Empyema prediction has evidence level L5 (model prediction only) — no clinical trials, no literature, and no marketing-authorisation basis in the UK.
- Mupirocin’s topical-only formulation makes systemic/deep-tissue delivery to the pleural space mechanistically implausible; the high TxGNN score should not be interpreted as clinical validation.
To proceed, the following is needed:
- Retrieval of the MHRA-approved SmPC warnings/contraindications (currently a blocking data gap, per this evidence pack)
- Confirmed mechanism-of-action documentation from DrugBank/product literature
- Any pharmacokinetic data demonstrating systemic or pleural-fluid penetration, if a non-topical formulation exists
- If no systemic formulation exists, this candidate should likely be deprioritised in favour of better-supported signals in the same evidence pack
Additional note for the reviewing pharmacist: within this same evidence pack, a different candidate — Staphylococcal Scalded Skin Syndrome (rank 9, TxGNN score 95.57%) — is far better supported, with 14 identified publications (including a retrospective cohort directly evaluating topical mupirocin combined with IV antibiotics), an evidence level of L3, and a “Proceed with Guardrails” recommendation. This is mechanistically consistent with Mupirocin’s known decolonisation role against toxin-producing S. aureus and may warrant a separate, dedicated evaluation report rather than being overshadowed by the Pleural Empyema top-score result.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.